
ECOG Performance status *	0	0 - Fully active, able to carry on all pre-disease performance without restriction						Baseline form			
	<ul> <li>1 - Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work</li> </ul>										
	<ul> <li>2 - Ambulatory and capable of all self care but unable to carry out any work activities. Up and about more than 50% of waking hours</li> </ul>										
	<ul> <li>3 - Capable of only limited self care, confined to bed or chair more than 50% of waking hours</li> </ul>										
	4 - Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair										
	O Not Available										
Hepatomegaly	0	Yes	0	No	Splenomegaly	0	Yes	0	No		
Pleural	0	Yes	0	No	Ascitic fluid analysis	0	Yes	0	No		
Waldeyer ring involvement	0	Yes	0	No	Histological diagnosis	0	Yes	0	No		
інс <b>⊕</b>	0	Yes	0	No	Bone marrow or peripheral blood based diagnosis Flow /IHC 1	0	Yes	0	No		
Type of Lymphoma *	0	Hoc	dgkins	s O r	Non Hodgkins CLL						
If Hodgkin's, then subtype	0	NLP	PHL	О сні	NS CHL, MC CHL, LP CHL, LD CHL, S	ubtyp	e unkr	nown			

Treatment given *	○ Yes   No	Initial Treatment plan
Type of RX plan *		and start of therapy  Debulking surgery Watchful waiting
Pre-phase used	O Yes O No	Pre-phase Date
If yes for pre-phase, specify Drugs		
Specify Dose		Specify Duration
Date of start of definitive treatment *		
Specify initial protocol used *		
For NHL patient	О СНОР	
	○ СОР	
	Bendamustine based	
	Oral chemotherapy	
	O EPOCH-DA	
	O Hyper-CVAD	
	Pediatric Burkitt-type protocols	Specify other
	GMALL NHL protocol	
	○ CHOP E	
	<ul> <li>Lenalidomide</li> </ul>	
	<ul> <li>Single agent rituximab</li> </ul>	
	○ FC	
	<ul> <li>Bendamustine</li> </ul>	
	O IBrutinib	
	O Venetoclax	
	<ul> <li>Lenalidomide</li> </ul>	
	Cladribine	
	O De Angelis	
	○ MTR	
	Other	Specify other
For Hodgkin' lymphoma	ABVD    Esc BEACOPP    S-	-BEACOPP O COPP O Oral chemotherapy O Other
1 51 97 31		
Specify Other		
For CLL	Benadmustine    FC    Chl	orambucil Other oral Single agent rituximab IBrutinib
	O Venetoclax O Other	
Specify Other		
Specify Other		
Rituximab used	O Yes O No	
Targeted therapy	O Yes O No	if yes, name
Other monoclonal antibodies used	O Yes O No	if yes, name
CNS directed therapy	O Yes O No	
		Huge No of Its
İT	Yes No	if yes, No. of ITs
HDMTX	O Yes O No	
Comments	9	
		the state of the s



Date of last follow up * 1	Follow up	Follow up			
Disease Status at last follow up *	○ CR ○ Not in CR ○ Palliation ○ Not Available				
Long term complications *6	○ Yes ○ No ○ Not known				
If yes, Specify <b>1</b>	Avascular necrosis Neuropathy Cardiac toxicity Pulmonary toxicity second malignancy Others	viral reactivation/ hepatitis			
Specify others					
Second malignancies	O Yes O No O Not known				
If yes, Specify second malignancies					
Comments					